Chemotherapy and Radiotherapy Regimens for Limited-Stage Small Cell Lung Cancer Treated With Accelerated...

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Standard treatment for limited-stage small cell lung cancer (LS-SCLC) involves chemotherapy and thoracic radiotherapy.
• High rates of disease recurrence persist despite standard treatment regimens.
• Optimizing treatment strategies is crucial for improving patient survival outcomes.

Purpose of the Study:

• To evaluate the impact of different chemotherapy and radiotherapy strategies on survival outcomes in LS-SCLC patients.
• To assess the association between chemotherapy cycle number and survival.
• To determine the effect of radiotherapy dose and interval on progression-free survival (PFS), overall survival (OS), and brain metastasis-free survival (BMFS).

Main Methods:

• Retrospective analysis of 201 LS-SCLC patients treated with chemotherapy and accelerated hyperfractionated radiotherapy.
• Progression-free survival (PFS) as the primary endpoint.
• Overall survival (OS) and brain metastasis-free survival (BMFS) as secondary endpoints.

Main Results:

• No significant survival difference was found between 4 cycles and 5-6 cycles of chemotherapy.
• Radiotherapy doses exceeding 45 Gy did not confer additional survival benefits compared to the standard 45 Gy dose.
• A radiotherapy interval greater than 75 days was associated with improved PFS (HR: 0.71, p=0.044).

Conclusions:

• Higher total radiotherapy doses do not significantly benefit LS-SCLC patients receiving accelerated hyperfractionated radiotherapy.
• A radiotherapy interval >75 days may improve PFS and OS, but requires prospective validation.
• 5-6 cycles of chemotherapy did not show significant benefits over 4 cycles for LS-SCLC.